Replies to post #262923 on Amarin Corp Plc (AMRN)

[hamkypamky]

The other issues are
1) supply chain of API and sales, distribution . Teva already has this established via their sale of G Lovaza
2) Teva's existing agreement with AMRN to pay AMRN a royalty if they enter the market . To my knowledge Hikma will not be paying AMRN any royalty if they enter therefore its in AMRN's interest ...if they lose the appeal ...that Teva enters .
3)AMRN has supply agreements / commitments already in place for API ( raw EPA ) and thus could supply Teva if necessary ...and supply of API will be an issue to really grow this market beyond $1B in yearly sales.

If Amarin loses the appeal ...then IMHO this is to big a market for Teva to allow a small generic competitor to dominate especially since Teva already has existing generic " fish oil " sales , supply , distribution structures in place

Generic Lovaza is a tiny tiny slice of TEVA's business today.

TEVA has a lot on their plate including branded drugs (which Kare is heavily focusing on given their good margins).

I dont see TEVA making a lot of effort to play in this space. They will do the necessary, but most likely not even close to the efforts that H&R will put in, given that the smaller companies are hungrier and have fewer revenue streams.